On 4 February 2025, Merck (known as MSD outside the US and Canada) revealed its Q4 and full year 2024 financial results, including reporting that global Keytruda® (pembrolizumab) sales for 2024 grew 18% (22% excluding the impact of foreign exchange) to US$29.5 billion.
MSD’s total pharmaceutical sales were up 7% for both Q4/2024 and for the full year, with global sales totalling US$57.4 billion. This is said to be largely due to increased oncology sales, including for Keytruda®.
Highlights for Q4 2024 are reported to include positive top-line results obtained in November 2024 from a Phase 3 trial evaluating SC pembrolizumab (MK-3475A), together with Alteogen’s berahyaluronidase alfa; FDA’s December 2024 acceptance of Merck’s BLA for clesrovimab (for protection of infants from respiratory syncytial virus (RSV) disease during their first RSV season); and global licences with LaNova for MK-2010, an investigational anti-PD-1/VEGF bispecific antibody, and with Hansoh Pharmaceutical for MK-4082, an investigational oral GLP-1 receptor agonist.